| Name | Title | Contact Details |
|---|
NanoLogix is a biotechnology company specializing in live cell, rapid diagnostics. Our kits are simple and reliable rapid test solutions that detect active threat bacteria and other microorganisms 4x - 12x faster than traditional Petri culture technology, and more cost effectively than PCR Protocol. NanoLogix FlatPack packaging allows for an extended shelf-life that is frequently more than double today's standard. In ongoing shelf-life tests, NanoLogix plates containing TSA media in FlatPacks have maintained nutrient and moisture levels for over two years in cold storage and over one year at room temperature (RT). Other agars have their usable shelf lives extended by varying amounts. NanoLogix plates can be used for isolating microorganisms, total plate count, and for maintaining stock cultures.
YM BioSciences Inc. is a Mississauga, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We have developed a high-sensitivity next-generation sequencing-based system for the detection of cancer mutations in miniscule concentrations of circulating cell-free DNA (cfDNA) in blood. Our technology addresses the significant barriers associated with harnessing the information contained in cfDNA by combining our proprietary techniques in molecular biology and computational algorithm for error suppression. With our technology, nanogram quantities of highly-fragmented cfDNA can be amplified more than 1000-fold, and a panel of tens to hundreds of cancer-related genes can be screened with a sensitivity at the single-digit molecular level.
Aldevron is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The Synlogic drug discovery engine is based on an engineering methodology that uses standardized and well-characterized interchangeable parts, as well as cutting-edge, logical gene-circuit control features. These unique and proprietary elements allow the scientific team to rapidly design, build and test synthetic life that leverage the microorganisms (bacteria and viruses) that live in and interact with the human body and transform them into programmable symbiotic living therapeutics that exhibit exquisite genetic control in response to pathophysiological signals. In a very short time, Synlogic has applied this platform to develop two lead programs in rare diseases that are advancing towards clinical development, as well as earlier programs in larger disease indications such as inflammation and metabolic diseases.